Do Traders Think Cytosorbents Corp (CTSO) Can Keep Climbing Tuesday?

Overall market sentiment has been high on Cytosorbents Corp (CTSO) stock lately. CTSO receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Cytosorbents Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CTSO!

See Full CTSO Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With CTSO Stock Today?

Cytosorbents Corp (CTSO) stock is trading at $1.32 as of 12:48 PM on Tuesday, Nov 21, a loss of -$0.08, or -5.71% from the previous closing price of $1.40. The stock has traded between $1.26 and $1.46 so far today. Volume today is light. So far 70,558 shares have traded compared to average volume of 107,867 shares. To screen for more stocks like Cytosorbents Corp click here.

More About Cytosorbents Corp

CytoSorbents Corp is a critical care immunotherapy leader commercializing its European Union approved CytoSorb blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients in around 55 countries. The company is conducting its pivotal REFRESH 2 - AKI cardiac surgery trial, designed to support U.S. FDA approval. The company's product portfolio consists of CytoSorb, ContrastSorb, VetResQ, HemoDefend and others. The company has around 19 issued U.S. patents, multiple patents issued internationally, and a broad patent application portfolio pending. Geographically it derives substantial revenue from product sales in Germany. Click Here to get the full Stock Report for Cytosorbents Corp stock.